Michael S. Grimley, MD
- Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- michael.grimley@cchmc.org
- Board Certified
About
Biography
I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.
Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.
As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.
My research involves finding treatments for and prevention of viral infections in immunocompromised patients.
When I’m not treating patients or involved in research, I enjoy spending time with my family.
MD: Emory University School of Medicine, Atlanta, GA, 1992,
Residency: Wilford Hall Medical Center, Lackland AFB, TX, 1995,
Fellowship: Cincinnati Children’s Hospital Medical Center, 1999,
Certifications: General Pediatrics, Pediatric Hematology/Oncology; Licenses: Ohio, Texas
Interests
Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Resolution of PML after Treatment with Virus-Specific T Cells and HCT. New England Journal of Medicine. 2026; 394(20):2061-2064.
Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT. Transplantation and Cellular Therapy. 2026.
LONG-TERM CRYOPRESERVATION PRESERVES THE BIOLOGICAL AND MECHANOBIOLOGICAL ACTIVITY OF THIRD-PARTY VIRUS-SPECIFIC T CELLS. Cytotherapy. 2026; 28(5):102608.
Intravenous Brincidofovir Effectively Reduces CMV Dnaemia In Antiviral Experienced Immunocompromised Patients: Results of a Phase 2a Clinical Trial. Transplantation and Cellular Therapy. 2026; 32(3):s19.
Duration of Cryopreservation of Third-Party Viral Specific T-Cells (TP-VSTs) Does Not Influence Clinical Efficacy. Transplantation and Cellular Therapy. 2026; 32(2):s131.
Bridging the Training Gap for Nurses and Advanced Practice Providers: Addition of in-Situ Simulations for Pediatric Transplant and Cellular Therapy Emergencies. Transplantation and Cellular Therapy. 2026; 32(2):s493-s494.
Improved Hematopoietic Stem Cell Mobilization for Gene Therapy of Hemoglobinopathies Using Single Agent Motixafortide. Transplantation and Cellular Therapy. 2026; 32(2):s20-s21.
Evaluating CMV Infection and Reactivation after Emapalumab: A Retrospective Evaluation of Letermovir Prophylaxis. Transplantation and Cellular Therapy. 2026; 32(2):s542.
Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major. Blood advances. 2025; 9(24):6370-6379.
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction. Blood advances. 2025; 9(24):6305-6313.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey